Oncologic outcomes according to the location and status of resection margin in pancreas head cancer: role of radiation therapy in R1 resection

다국어 초록 (Multilingual Abstract)

Purpose: The clinical significance of margin status in pancreatic head cancer is still controversial due to the nonstandardized definition of R status and pathologic reporting. This study aims to evaluate the impact of the margin status including location and the role of radiation therapy in pancreatic head cancer.
Methods: A total of 314 patients who underwent curative-intent surgery for pancreatic head cancer between 2010 and 2017 were analyzed. Demographics, survival, and local recurrences were compared according to 2 definitions: 0-mm R1 as direct involvement and 1-mm R1 as close resection margin less than 1 mm. The specific margins were divided into 4 groups according to the location around the pancreas: pancreas transection, anterior surface, posterior surface, and vessel (superior mesenteric artery/superior mesenteric vein) margin.
Results: The 0-mm R1-rate was 15.6%, and increased to 36.3% in 1-mm R1. The median overall survival rate of 0-mm R0 vs. R1 was 26 months vs. 16 months (P = 0.052) and that of 1-mm R0 vs. R1 was 27 months vs. 18 months, respectively (P = 0.016). In individual margins, posterior, anterior surface, and pancreas transection margin involvement were associated with poor outcome, and the 1 mm posterior surface involvement was an independent risk factor for disease-free survival (hazard ratio, 1.63). Adjuvant radiation therapy had oncologic benefits, especially in R1 patients (P = 0.011) compared to R0 patients (P = 0.088).
Conclusion: Margin status, especially 1-mm R1 status is an important predictive factor, and involved posterior surface has a clinical impact. Patients with positive margins should be considered adjuvant radiation therapy.

목차 (Table of Contents)

• INTRODUCTION
• METHODS
• RESULTS
• DISCUSSION
• REFERENCES

참고문헌 (Reference)

1 Adsay NV, "Whipple made simple for surgical pathologists : orientation, dissection, and sampling of pancreaticoduodenectomy specimens for a more practical and accurate evaluation of pancreatic, distal common bile duct, and ampullary tumors" 38 : 480-493, 2014

2 Sajjad M, "Use of radiation therapy in locally advanced pancreatic cancer improves survival : a SEER database analysis" 41 : 236-241, 2018

3 Verbeke CS, "Tumour growth is more dispersed in pancreatic head cancers than in rectal cancer : implications for resection margin assessment" 59 : 1111-1121, 2011

4 Hruban RH, "Tumors of the pancreas. AFIP Atlas of tumor pathology" Armed Forces Institute of Pathology 2007

5 Kimbrough CW, "Tumorpositive resection margins reflect an aggressive tumor biology in pancreatic cancer" 107 : 602-607, 2013

6 Ethun CG, "The importance of surgical margins in pancreatic cancer" 113 : 283-288, 2016

7 Ghaneh P, "The impact of positive resection margins on survival and recurrence following resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma" 269 : 520-529, 2019

8 Gill AJ, "Synoptic reporting improves histopathological assessment of pancreatic resection specimens" 41 : 161-167, 2009

9 Kim BH, "Survival benefit of adjuvant chemoradiotherapy for positive or close resection margin after curative resection of pancreatic adenocarcinoma" 46 : 2122-2130, 2020

10 Osipov A, "Redefining the positive margin in pancreatic cancer : impact on patterns of failure, long-term survival and adjuvant therapy" 24 : 3674-3682, 2017

11 Verbeke CS, "Redefining the R1 resection in pancreatic cancer" 93 : 1232-1237, 2006

12 Jamieson NB, "Positive mobilization margins alone do not influence survival following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma" 251 : 1003-1010, 2010

13 Delpero JR, "Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens" 16 : 20-33, 2014

14 Strobel O, "Pancreatic cancer surgery : the new R-status counts" 265 : 565-573, 2017

15 Hidalgo M, "Pancreatic cancer" 362 : 1605-1617, 2010

16 de Geus SW, "Neoadjuvant therapy affects margins and margins affect all: perioperative and survival outcomes in resected pancreatic adenocarcinoma" 20 : 573-581, 2018

17 Campbell F, "Minimum dataset for histopathological reporting of pancreatic, ampulla of vater and bile duct carcinoma" Royal College of Pathologists 2002

18 Gnerlich JL, "Microscopic margins and patterns of treatment failure in resected pancreatic adenocarcinoma" 147 : 753-760, 2012

19 Chandrasegaram MD, "Metaanalysis of radical resection rates and margin assessment in pancreatic cancer" 102 : 1459-1472, 2015

20 Chang DK, "Margin clearance and outcome in resected pancreatic cancer" 27 : 2855-2862, 2009

21 Schnelldorfer T, "Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma : is cure possible?" 247 : 456-462, 2008

22 Yamamoto T, "Long-term sur vival after resection of pancreatic cancer : a singlecenter retrospective analysis" 21 : 262-268, 2015

23 Castellanos JA, "Intensity of follow-up after pancreatic cancer resection" 21 : 747-751, 2014

24 Butturini G, "Influence of resection margins and treatment on survival in patients with pancreatic cancer : meta-analysis of randomized controlled trials" 143 : 75-83, 2008

25 Tummers WS, "Impact of resection margin status on recurrence and survival in pancreatic cancer surgery" 106 : 1055-1065, 2019

26 Conroy T, "FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer" 379 : 2395-2406, 2018

27 Schlitter AM, "Definition of microscopic tumor clearance(r0)in pancreatic cancer resections" 2 : 2001-2010, 2010

28 Takahashi C, "Adjuvant therapy for margin positive pancreatic cancer" 36 (36): 390-, 2018

29 Oettle H, "Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer : the CONKO-001 randomized trial" 310 : 1473-1481, 2013

30 Neoptolemos JP, "A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer" 350 : 1200-1210, 2004